ArticleOncology letters2018
Mitochondrial ROS contribute to oridonin-induced HepG2 apoptosis through PARP activation.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Redox-modulation of regulated cell death: implications for synergistic anticancer therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Vonoprazan as an adjuvant to cisplatin: enhancing antitumor efficacy while mitigating nephrotoxicity and gastrointestinal adverse effects.Frontiers in pharmacology · 2026Article
- ε-Viniferin Rejuvenates Senescence viaPharmaceuticals (Basel, Switzerland) · 2025Article
- Semisynthesis and Antitumour Evaluation of Natural Derivatives fromInternational journal of molecular sciences · 2024Article
- Targeting Mitochondrial Oxidative Stress as a Strategy to Treat Aging and Age-Related Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- The abrupt pathological deterioration of cisplatin-induced acute kidney injury: Emerging of a critical time point.Pharmacology research & perspectives · 2021Article
- Chemical diversity of dietary phytochemicals and their mode of chemoprevention.Biotechnology reports (Amsterdam, Netherlands) · 2021Review
- Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity.Frontiers in pharmacology · 2021Review
- Crizotinib changes the metabolic pattern and inhibits ATP production in A549 non-small cell lung cancer cells.Oncology letters · 2021Article
- Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway.Journal of cellular and molecular medicine · 2020Article
- Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway.Cancer management and research · 2020Article
- Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.Chinese medicine · 2019Review
- Involvement of Glutathione Depletion in Selective Cytotoxicity of Oridonin to p53-Mutant Esophageal Squamous Carcinoma Cells.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oridonin, the main active constituent of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.